Table 1. Characteristics of patients... | American Society of Hematology

Table 1.

Characteristics of patients

Characteristic, N = 58	Median (range) or n (%)
Female sex	16 (28)
Age, y	62 (41-75)
Diagnosis period	6/2/2014 (1/29/2010-5/23/2018)
Follow-up of surviving patients for survival from ASCT, mo	59 (24-110)
High-risk FISH*	13 (22)
Type of induction therapy
IMID-based	43 (73)
At least triplet therapy	49 (84)
Interval, diagnosis to ASCT, mo	6 (1-11.6)
Hematologic response prior to ASCT
CR	19 (33)
VGPR	19 (33)
PR	14 (24)
< PR	6 (10)
Engraftment syndrome	6 (10)
Hematologic response post-ASCT
CR	24 (41)
VGPR	17 (29)
PR	11 (19)
<PR	6 (10)
Maintenance therapy
IMID based	26 (45)
Single agent	27 (47)
Combination therapy	8 (13)
No maintenance†	23 (40)
Outcomes post maintenance
Time to relapse, mo	17 (2-83)
Relapse within 12 mo	14 (24)
Remission lasting >36 mo with maintenance	10 (17)
Remission lasting >18 mo without maintenance	11 (9)

Characteristic, N = 58	Median (range) or n (%)
Female sex	16 (28)
Age, y	62 (41-75)
Diagnosis period	6/2/2014 (1/29/2010-5/23/2018)
Follow-up of surviving patients for survival from ASCT, mo	59 (24-110)
High-risk FISH*	13 (22)
Type of induction therapy
IMID-based	43 (73)
At least triplet therapy	49 (84)
Interval, diagnosis to ASCT, mo	6 (1-11.6)
Hematologic response prior to ASCT
CR	19 (33)
VGPR	19 (33)
PR	14 (24)
< PR	6 (10)
Engraftment syndrome	6 (10)
Hematologic response post-ASCT
CR	24 (41)
VGPR	17 (29)
PR	11 (19)
<PR	6 (10)
Maintenance therapy
IMID based	26 (45)
Single agent	27 (47)
Combination therapy	8 (13)
No maintenance†	23 (40)
Outcomes post maintenance
Time to relapse, mo	17 (2-83)
Relapse within 12 mo	14 (24)
Remission lasting >36 mo with maintenance	10 (17)
Remission lasting >18 mo without maintenance	11 (9)

Defined as the presence of t(4;14), del(17/17p), t(14;16), or t(14;20).

Of which 3 were primary refractory and as a result switched therapy.

IMID, immunomodulatory drug (thalidomide, lenalidomide, pomalidomide); NR, no response/disease progression.